{
  "docId": "019de074-753e-742e-8482-2e45ed67d022",
  "docSlug": "1014e5ae1361495c3b249a754ba0dfae",
  "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 22,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a combination of clinical trial charts and a logo-grid of scientific journals to establish credibility.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/8",
  "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022",
  "deckJsonHref": "/decks/019de074-753e-742e-8482-2e45ed67d022.json",
  "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.38,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clear Clinical Benefit in ITP",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a354d89-9951-4680-a8ac-3243a417f393",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "SC Noninferiority to IV",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72465de2-fe99-476f-be9c-61d7508e81fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "image",
      "text": "Logos of Frontiers in Immunology, SID, Cells, ACR, The Journal of Immunology",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81102b5b-e240-40bf-91df-78e3694e5bc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "list",
      "text": ">1,300 clinical study subjects; Cyclic and chronic dosing; Cumulative exposure of >1,000 patient years; TEAEs consistent across >4 indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d20315d9-bf3a-4c00-a140-df68aea4a67f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "title",
      "text": "Solidifying FcRn Leadership with Deep Repertoire of Preclinical and Translational Data",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54c13100-a2bb-44a9-be26-5375410a3574",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "2022: Strengthened Efgartigimod Data Story",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ea860fc-6530-4227-99a7-8acf6f2dcb26",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "e1021ed1-ab42-440c-b014-d5f819619d38",
      "evidence": "Solidifying FcRn Leadership with Deep Repertoire of Preclinical and Translational Data",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "1dcc921b-605f-4037-bec6-17c767f15212",
      "evidence": "Use of academic journal logos to validate clinical data",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715",
      "evidence": "The presentation sets up the current situation and unmet needs.",
      "position": 0,
      "objective": "Why now is the right time for argenx SE's mission",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}